Abstract
Several studies have recently shown that the combined treatment of tumor-bearing animals with multiple cytokines results in a more potent antitumor effect than single cytokine therapy (1–9).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
S. Silagi, R. Dutkowski, and A. Schaefer, Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma, Int. J. Cancer., 41:315 (1988).
J. K. McIntosh, J. J. Mulé, M. J. Merino, and S. A. Rosenberg, Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha, Cancer Res., 48:4011 (1988).
M. J. Brunda, D. Bellantoni, and V. Sulich, In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells, Int. J. Cancer., 40:365 (1987).
J. L. Winkelhake, S. Stampfl, and R. J. Zimmerman, Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models, Cancer Res., 47:3948 (1987).
J. K. McIntosh, J. J. Mulè, J. A. Krosnick, and S. A. Rosenberg, Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice, Cancer Res., 49:1408 (1989).
M. Iigo, M. Sakurai, T. Tamura, N. Saijo, and A. Hoshi, In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon on various syngeneic murine tumors, Cancer Res., 48:260 (1988).
S. A. Rosenberg, S. L. Schwarz, and P. J. Spiess, Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alpha interferon, and tumor-infiltrating lymphocytes, J. Natl. Cancer Inst., 80:1393 (1988).
F. Belardelli, V. Ciolli, U. Testa, E. Montesoro, D. Bulgarini, E. Proietti, P. Borghi, P. Sestili, C. Locardi, C. Peschle, and I. Gresser, Antitumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors, Int. J. Cancer, 44:1108 (1989).
V. Ciolli, L. Gabriele, P. Sestili, F. Varano, E. Proietti, I. Gresser, U. Testa, E. Montesoro, D. Bulgarini, G. Mariani, C. Peschle, F. Belardelli, Host antitumor mechanisms in the combined IL-1/IL-2 therapy in mice injected with highly metastatic Friend leukemia cells. Effects on established metastases, J. Exp. Med., 173:313 (1991).
F. Belardelli, I. Gresser, C. Maury, and M. T. Maunoury, Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I, Int. J. Cancer., 30:813 (1982).
F. Belardelli, I. Gresser, C. Maury, P. Duvillard, M. Prade, and M. T. Maunoury, Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously, Int. J. Cancer, 31:649 (1983).
I. Gresser, C. Maury, D. Woodrow, J. Moss, M. G. Grutter, F. Vignaux, F. Belardelli, and M. T. Maunoury, Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells, Int. J. Cancer, 41:135 (1988).
I. Gresser, F. Belardelli, J. Tavernier, W. Fiers, F. Podo, M. Federico, G. Carpinelli, P. Duvillard, M. Prade, C. Maury, M. T. Bandu, and M. T. Maunoury, Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. V. Comparison with the action of tumor necrosis factor, Int. J. Cancer, 38:771 (1986).
E. Proietti, F. Belardelli, G. Carpinelli, M. Di Vito, D. Woodrow, J. Moss, P. Sestili, W. Fiers, I. Gresser, and F. Podo, Tumor necrosis factor alpha induces early morphologic and metabolic alterations in Friend leukemia cell tumors and fibrosarcomas in mice, Int. J. Cancer, 42:582 (1988).
F. Belardelli, E. Proietti, V. Ciolli, P. Sestili, G. Carpinelli, M. Di Vito, A. Ferretti, D. Woodrow, D. Boraschi, and F. Podo, Interleukin-lβ induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the antitumor effects of tumor necrosis factor α or β, Int. J. Cancer, 44:116 (1989).
E. Affabris, C. Jemma, and G.B. Rossi, Isolation of interferon-resistant variants of Friend erythroleukemia cells: effect of interferon and ouabain, Virology, 120:441 (1982).
F. Belardelli, M. Ferrantini, C. Maury, L. Santurbano, and I. Gresser, On the biologic and biochemical differences between in vitro and in vivo passaged Friend Erythroleukemia Cells I. Tumorigenicity and capacity to metastasize, Int. J. Cancer, 34:389 (1984).
K. Bosslet and V. Schirrmacher, High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb), Int. J. Cancer, 29:195 (1982).
M. G. Tovey, J. Begon-Lours, I. Gresser, A method for the large-scale production of potent interferon preparations, Proc. Soc. Exp. Biol. Med., 146:809 (1974).
I. Gresser, C. Maury, C. Carnaud, E. De Maeyer, M. T.Maunoury, and F. Belardelli, Antitumor effects of Interferon in mice injected with Interferon-sensitive and Interferon-resistant Friend Erythroleukemia Cells. VIII. Role of the immune system in the inhibition of visceral metastases, Int. J. Cancer, 46:468 (1990).
P. G. Braunschweiger, C.S. Johnson, N. Kumar, V. Ord, and P. Furmanski, Antitumor effects of recombinant human interleukin 10 in RIF-1 and Panc02 solid tumors, Cancer Res., 48:6011 (1988).
S. Nakamura, K. Nakata, S. Kashimoto, H. Yoshida, and M. Yamada, Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors, Jpn. J. Cancer Res. (Gann), 77:767 (1986).
R. J. North, R.H. Neubauer, J.J.H. Huang, R.C. Newton, and S.E. Loveless, Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity, J. Exp. Med., 168:2031 (1988).
M. A. Palladino, M. R. Shalaby, S. M. Kramer, B. L. Ferraiolo, R. A. Baughman, A. B. Deleo, D. Crase, B. Marafino, B. B. Aggarwal, I. S. Figari, D. Liggitt, and J. S. Patton, Characterization of the antitumor activities of human tumor necrosis factor-a and the comparison with other cytokines: induction of tumor specific immunity, J. Immunol., 138:4023 (1987).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Belardelli, F., Gabriele, L., Proietti, E., Testa, U., Peschle, C., Gresser, I. (1992). Mechanisms of Combined IL-1/IL-2 and IL-1/IFN Therapy in Mice Injected with Metastatic Tumor Cells. In: Goldstein, A.L., Garaci, E. (eds) Combination Therapies. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3340-5_34
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3340-5_34
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6472-6
Online ISBN: 978-1-4615-3340-5
eBook Packages: Springer Book Archive